Get the Stockscreener App
1.03
0.96%
-0.01
After Hours:
1.02
-0.01
-0.97%
Revelation Biosciences Inc stock is traded at $1.03, with a volume of 21,948.
It is down -0.96% in the last 24 hours and down -10.04% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
See More
Previous Close:
$1.04
Open:
$1.03
24h Volume:
21,948
Relative Volume:
0.26
Market Cap:
$4.03M
Revenue:
-
Net Income/Loss:
$-8.91M
P/E Ratio:
-0.0265
EPS:
-38.8702
Net Cash Flow:
$-8.27M
1W Performance:
-0.96%
1M Performance:
-10.04%
6M Performance:
-69.84%
1Y Performance:
-91.80%
1-Day Range:
$0.9926
$1.045
1-Week Range:
$0.96
$1.07
52-Week Range:
$0.875
$13.08
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
1.03 | 4.06M | 0 | -8.91M | -8.27M | -38.87 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Revelation Biosciences Inc Stock (REVB) Latest News
Revelation Biosciences (REVB) Stock Forum and Discussion - Moomoo
Revelation Biosciences, Inc.Common Stock (NQ: REVB - The Chronicle-Journal
Armistice Capital reports 323,241 REVB shares (REVB) — 7.80% stake disclosed - Stock Titan
TradingKey - TradingKey
REVB Stock Price, Quote & Chart | REVELATION BIOSCIENCES INC (NASDAQ:REVB) - ChartMill
Revelation Biosciences (NASDAQ: REVB) seeks wide reverse split authority in 2026 proxy - Stock Titan
Revelation Biosciences releases proxy materials with CEO update - Investing.com
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders - New Castle News
How one 300-patient trial could unlock a new acute kidney injury treatment - Stock Titan
The edge Revelation Biosciences (REVB) has in a competitive landscape (Risk Aversion) 2026-05-08Verified Stock Signals - newser.com
EX-99.1 - SEC.gov
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 - Times Argus
Q1 2026 results for Revelation Biosciences (NASDAQ: REVB) detailed - Stock Titan
FDA agrees to single Gemini study for acute kidney injury - Stock Titan
BRIEF-Revelation Biosciences Inc Q1 EPS USD -2.71 - TradingView
Revelation Biosciences (REVB) Q1 loss widens as cash runway and going concern risks emerge - Stock Titan
Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Revelation Biosciences Inc expected to post a loss of $1.15 a shareEarnings Preview - TradingView
Revelation Biosciences (REVB) CEO has shares sold to cover tax withholding - Stock Titan
Revelation Biosciences (REVB) CFO reports tax-withholding share sale via trust - Stock Titan
Revelation Biosciences (NASDAQ: REVB) asks shareholders to approve wide reverse split - Stock Titan
REVB Revelation Biosciences reports vastly wider Q4 2025 loss than estimates, shares end flat for the trading day.Beat Estimates - newser.com
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - The Sheboygan Press
REVB Revelation Biosciences posts massive Q4 2025 EPS shortfall on zero revenue, shares remain unchanged.Operational Risk - Cổng thông tin điện tử tỉnh Tây Ninh
REVB (Revelation Biosciences Inc.) posts drastically wider than expected Q4 2025 loss, sending its stock down 4.76% in today’s trading.EBITDA Margin - UBND thành phố Hải Phòng
REVB (Revelation Biosciences Inc.) falls 4.58% today after Q4 2025 EPS misses estimates by a staggering 541.5%. - UBND thành phố Hải Phòng
Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’ - MSN
Aug Setups: Is Revelation Biosciences Inc Equity Warrant showing insider buyingQuarterly Earnings Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Sectors: What is the Moat Score of Revelation Biosciences Inc2026 Momentum Check & Advanced Technical Analysis Signals - baoquankhu1.vn
Forecast Cut: Can Revelation Biosciences Inc Equity Warrant grow without dilution2026 Catalysts & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Aug Decliners: What are the risks of holding Revelation Biosciences IncQuarterly Profit Report & Daily Technical Forecast Reports - baoquankhu1.vn
REVB Technical Analysis & Stock Price Forecast - Intellectia AI
Fed Meeting: Will Revelation Biosciences Inc Equity Warrant benefit from green energy policiesEarnings Summary Report & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Support Test: What is Revelation Biosciences Inc Equity Warrants valuation compared to sector2026 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
Stock Market Recap: Can Revelation Biosciences Inc keep up with sector leadersWeekly Profit Analysis & Smart Swing Trading Alerts - baoquankhu1.vn
US Market Wrap: Is Revelation Biosciences Inc Equity Warrant showing insider buyingWeekly Trade Analysis & Real-Time Price Movement Reports - baoquankhu1.vn
Revelation Biosciences forms advisory board for AKI trial By Investing.com - Investing.com Australia
Chart Watch: Does Revelation Biosciences Inc Equity Warrant stock benefit from AI growthDip Buying & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Revelation Biosciences Forms Acute Kidney Injury Advisory Board - National Today
Revelation Biosciences forms advisory board for AKI trial - Investing.com
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board - ACCESS Newswire
Kidney injury trial draws 5 specialists to guide Revelation study - Stock Titan
REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Wrap: Will Revelation Biosciences Inc Equity Warrant benefit from green energy policies2026 Trade Ideas & Stepwise Trade Execution Plans - baoquankhu1.vn
History Review: What is Revelation Biosciences Inc Equity Warrants valuation compared to sectorWeekly Investment Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Short Squeeze: Is Revelation Biosciences Inc Equity Warrant backed by strong institutional buying2026 Momentum & Stepwise Trade Signal Implementation - baoquankhu1.vn
Returns Recap: Is Revelation Biosciences Inc Equity Warrant stock influenced by commodity prices2026 Short Interest & Weekly Breakout Watchlists - baoquankhu1.vn
Sectors Review: What are the risks of holding Revelation Biosciences IncTrade Exit Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Aug Closing: Can Revelation Biosciences Inc Equity Warrant grow without dilution2026 Momentum Check & Community Shared Stock Ideas - baoquankhu1.vn
Revelation Biosciences Presents Positive Data from Prime Clinical Study - National Today
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study - ACCESS Newswire
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.19%
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):